Inclusion Criteria:

- 18 years of age or older

- Solid tumors refractory to conventional therapy or the subject does not tolerate the
conventional therapy

- Evaluable disease or at least one measurable tumor mass by a radiographic technique

- Life expectancy ≥3 months

- Suitable for intravenous administration of study medication

- Signed written informed consent

- Adequate bone marrow, renal, and liver function

- Coagulation profile with aPTT and INR, each ≤ 1.5 x ULN

- No evidence of active Hepatitis B or Hepatitis C infection

- Proteinuria <100 mg

- ECOG performance status ≤2

- Female subjects must agree to use contraceptive measures

- Negative serum ß-hCG

- Ability and willingness to comply with the study protocol

Exclusion Criteria:

- Pregnant or lactating women

- Therapy with systemic anticoagulant or antithrombotic agentswithin 7 days prior to
first dose

- Hemoptysis within 3 months prior to first dose

- Cytotoxic chemotherapy, immunotherapy, or radiotherapy within 4 weeks prior to first
dose

- Surgery or visceral biopsy within 28 days prior to first dose

- Minor surgical procedure performed within 7 days prior to first dose

- Prior exposure to MG1102

- Known history of HIV

- With active bacterial infections and/or receiving systemic antibiotics

- Current or past diagnosis of leukemia

- Known CNS metastases or clinical evidence of CNS

- Non-healing wound within past 2 weeks

- Bleeding diathesis or bleeding within 14 days prior to enrollment

- Clinically significant thrombosis

- Non-malignant GI bleeding, gastric stress ulcerations, or peptic ulcer disease

- History of idiopathic or hereditary angioedema

- History of sickle cell or any hemolytic anemia

- Require hemoglobin, WBC, or platelet transfusion support or use of hematopoietic
growth factors within 2 weeks prior to entry

- Uncontrolled hypertension

- History of clinically significant renal disease

- History of significant medical illness of cardiac or CNS disease within the past 6
months

- Treatment with an investigational agent within the longest time frame of either 5
half-lives or 30 days of initiating study drug

- Medical or psychiatric illness

- Recreational substance use or psychiatric illness

- Known hypersensitivity to MG1102 or components of the formulation